FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYTR), developer and manufacturer of the first FDA-approved active patch transdermal drug delivery system (LidoSite®) and a leader in active transdermal drug delivery technology, announced the establishment of its Business Development Team. Vyteris’ Business Development Team will focus on attracting opportunities with biopharma companies and others to jointly develop products involving delivery of compatible drugs with Vyteris’ patented Smart Patch transdermal drug delivery technology.
